Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Comment by minedrilleron Aug 11, 2020 1:32pm
263 Views
Post# 31393641

RE:What is everyone's thoughts on Financials

RE:What is everyone's thoughts on FinancialsAll the companies financials are there for look see, but something tells me, you don't want that you just want the go go go to put down your bucks. So to spell it out for you ... Well if you want to know they messed up two Phase 2s, the latest was a slam dunk and was as near to certainty as could be possible  and was a big surprise in the corrupt pharm sector (9 out of 10 """"experts""""" said this was going to get through). This company should be at least $20 pending $100 plus by now (let that sink in) that's why there’s so many orbiters hovering around now as they couldn't get in the first time. It's simple, you want to take the risk after the idiot management messed up not once, but TWICE (both time the same explanation was provided, and I quote "doesn't make sense errrr ehhhh" then silence) then do so. 

<< Previous
Bullboard Posts
Next >>